{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-124836","form_type":"8-K","ticker":"OCGN","cik":"0001372299","company_name":"Ocugen, Inc.","filed_at":"2026-11-10T13:30:22+00:00","discovered_at":"2026-11-10T13:35:00.289907+00:00","generated_at":"2026-11-10T13:35:04.971852+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Ocugen licenses OCU400 to Celairis for Australia, New Zealand and ASEAN; up to $7.1M in payments plus royalties","bullets":["Celairis gets exclusive rights to commercialize OCU400, Ocugen's investigational modifier gene therapy for retinitis pigmentosa, in Australia, New Zealand and ASEAN markets.","Ocugen receives an upfront fee plus development/milestone payments up to $7.1M, including $6.1M tied to the upfront payment and Phase 3 liMeliGhT top-line data expected in Q1 2027.","Separate $1.0M milestone payable on Therapeutic Goods Administration approval in Australia; Ocugen also gets a high single-digit percentage royalty on net sales and 50% of gross profits.","Ocugen retains sole manufacturing rights and the parties target a supply agreement within 90 days; territory covers an estimated 725 million people and can expand by mutual agreement.","Ocugen calls it the third strategic regional partnership for OCU400; U.S. BLA and EU MAA filings are planned after the Q1 2027 topline readout."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-124836","json":"https://secwatch.observer/filing/0001104659-26-124836.json","markdown":"https://secwatch.observer/filing/0001104659-26-124836.md","text":"https://secwatch.observer/filing/0001104659-26-124836.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926124836/0001104659-26-124836-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926124836/tm2629434d1_8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-11-10T13:35:04.971852+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}